Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 7, 2013 - Issue sup2
Submit an article Journal homepage
122
Views
2
CrossRef citations to date
0
Altmetric
Questions & Answers

Which is the optimal bronchodilator therapy for chronic obstructive pulmonary disease?

Adolfo Baloira Department of Pulmonology, Pontevedra Hospital Complex, Galicia, Spain. [email protected]
Pages 17-24 | Published online: 09 Jan 2014

References

  • Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320(7245), 1297–1303 (2000).
  • Calverley PM, Anderson JA, Celli B et al.; TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356(8), 775–789 (2007).
  • Vestbo J, Edwards LD, Scanlon PD et al.; ECLIPSE Investigators. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 365(13), 1184–1192 (2011).
  • Hanania NA, Sharafkhaneh A, Celli B et al. Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir. Res. 12(</Is>), 6 (2011).
  • Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest 126(2 Suppl), 125S–137S; discussion 159S (2004).
  • Albert P, Agusti A, Edwards L et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 67(8), 701–708 (2012).
  • Soler-Cataluña JJ, Cosío B, Izquierdo JL et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch. Bronconeumol. 48(9), 331–337 (2012).
  • Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest 96(5), 984–987 (1989).
  • Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA 300(12), 1439–1450 (2008).
  • illeman DE, Malesker MA, Morrow LE, Schuller D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 4(</Is>), 253–263 (2009).
  • Estwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir. Res. 12(</Is>), 40 (2011).
  • Amirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients with COPD. Chest 112(2), 336–340 (1997).
  • ahl R, Greefhorst LA, Nowak D et al.; Formoterol in Chronic Obstructive Pulmonary Disease I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 164(5), 778–784 (2001).
  • asaburi R, Mahler DA, Jones PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 19(2), 217–224 (2002).
  • ones PW, Mahler DA, Gale R, Owen R, Hramer B. Profiling the effects of indacaterol on dyspnea and health status in patients with COPD. Respir. Med. 105, 892–899 (2011).
  • Donohue JF, Fogarty C, Lötvall J et al.; INHANCE Study Investigators. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 182(2), 155–162 (2010).
  • COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease a combination of ipratropium and albuterol is more effective than either agent alone. Chest 105, 1411–1419 (1994).
  • D’Urzo AD, De Salvo MC, Ramirez-Rivera A et al.; FOR-INT-03 Study Group. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 119(5), 1347–1356 (2001).
  • van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur. Respir. J. 15(5), 878–885 (2000).
  • Vincken W, van Noord JA, Greefhorst AP et al.; Dutch/Belgian Tiotropium Study Group. Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium. Eur. Respir. J. 19(2), 209–216 (2002).
  • Dahl R, Chung KF, Buhl R et al.; INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 65(6), 473–479 (2010).
  • Kornmann O, Dahl R, Centanni S et al.; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur. Respir. J. 37(2), 273–279 (2011).
  • Baloira Villar A, Vilariño Pombo C. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease]. Arch. Bronconeumol. 41(3), 130–134 (2005).
  • Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 63(7), 592–598 (2008).
  • van Noord JA, Aumann JL, Janssens E et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir. Med. 104(7), 995–1004 (2010).
  • Cazzola M, Andò F, Santus P et al. A pilot study to assess the effects of combining fluticasone/salmeterol and tiotropium on the airway obstruction of patients with severe-to-very severe COPD. Pulm. Pharmacol. Ther. 20, 556–561 (2007).
  • Aaron SD, Vandemheen KL, Fergusson D et al.; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 146(8), 545–555 (2007).
  • van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 26(2), 214–222 (2005).
  • Vogelmeier C, Kardos P, Haari S, Gans SL, Stenglein S, Thirlvell J. Formoterol mono-and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir. Med. 102, 1511–1520 (2008).
  • Rabe KF, Timmer W, Sagkriotis A, Viel K. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 134(2), 255–262 (2008).
  • elte T, Miravitlles M, Hernandez P et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 180(8), 741–750 (2009).
  • Mahler DA, D’Urzo A, Bateman ED et al.; INTRUST-1 and INTRUST-2 study investigators. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 67(9), 781–788 (2012).
  • van Noord JA, Buhl R, Laforce C et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax 65(12), 1086–1091 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.